Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Dementia is the umbrella term for all kinds of conditions associated with memory loss of which Alzheimer’s disease is the ...

No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

Understanding the symptoms of cirrhosis can facilitate early diagnosis and intervention, improving outcomes for those ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...

Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

These antiemetics are more important than ever given that newer oral anticancer drugs are often associated with more constant nausea and vomiting ... rides or going without pain medications ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

Low blood pressure, or hypotension, is not necessarily serious. Chronic low blood pressure, so long as it is without ...

For most people diagnosed with diabetes, the desirable A1C goal is seven percent or less as higher levels are linked to ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...